Ignite Creation Date:
2024-05-06 @ 6:44 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05765084
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2023-02-13
Brief Title:
Integration of the PD-L1 Inhibitor Atezolizumab and WT1DC Vaccination Into PlatinumPemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Sponsor:
Organization:
University Hospital Antwerp
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
15
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: